Overview

Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy (HOST-EXAM)

Status:
Completed
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
Objectives : To compare the efficacy and safety of clopidogrel monotherapy with aspirin monotherapy in patients who received dual or triple antiplatelet therapy for 1 year (± 6 months) after drug-eluting stent implantation for coronary artery disease Patient Enrollment : 5530 patients enrolled at 55 centers in Korea Patient Follow-up : Clinical follow-up will occur at 1, 12 and 24 months. Primary Endpoint : Composite endpoint of MACE and major bleeding Secondary Endpoint : Device-oriented composite outcome including TLR (target lesion revascularization), TVR (target vessel revascularization), stent thrombosis, and minor GI (gastrointestinal) complications
Phase:
Phase 4
Details
Lead Sponsor:
Seoul National University Hospital
Collaborators:
Chong Kun Dang Pharmaceutical
Daewoong Pharmaceutical Co. LTD.
HANMI PHARMA CO.,Ltd
Hanmi Pharmaceutical co., ltd.
Samjin Pharmaceutical Co., Ltd.
Treatments:
Aspirin
Clopidogrel
Ticlopidine